Skip to content

Zevra Therapeutics, Inc. ZVRA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$847K-82.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$241K+1,105%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$2.2M-13.1%
PVL
Palvella TherapeuticsPVLA
$230M
Arrowhead Research logo
Arrowhead ResearchARWR
$46.83M

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s stock issuance proceeds?
Zevra Therapeutics, Inc. (ZVRA) reported stock issuance proceeds of $752K in Q1 2026.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.